Biomarkers for the prognosis of severe dengue;Biomarcadores pronósticos de gravedad del dengue

Biomedica

Volumn 33, Issue SUPPL.1, 2013, Pages 108-116

  Villar, Luis Angel ^a,b   Gélvez, Rosa Margarita ^a,b   Rodríguez, Jairo Antonio ^b,c   Salgado, Doris ^b,c   Parra, Beatriz ^b,d   Osorio, Lyda ^b,d   Bosch, Irene ^e  

^a UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

^b Dengue para el Estudio de su Severidad ^*  (Colombia)

^c UNIVERSIDAD SURCOLOMBIANA   (Colombia)

^d UNIVERSIDAD DEL VALLE   (Colombia)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Capillary permeability; Cytokines; Dengue; Forecasting; Humans; Inflammation; Severity of illness index

Indexed keywords

BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; INDOLEAMINE 2,3-DIOXYGENASE 2, HUMAN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOLESCENT; ADULT; AGED; BLOOD; CASE CONTROL STUDY; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; DENGUE; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PRESCHOOL CHILD; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CELL SURFACE; SEVERE DENGUE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84890829231     PISSN: 01204157     EISSN: None     Source Type: Journal    
DOI: 10.7705/biomedica.v33i0.733     Document Type: Article

References (40)

1. Organización Panamericana de la Salud, Organización Mundial de la Salud. Dengue: guías para el diagnóstico, tratamiento, prevención y control. Fecha de consulta: 20 de enero de 2012. Disponible en: http://www.ops.org.bo/textocompleto/ndeng31482.pdf.
2. Padilla JC, Rojas DP, Sáenz R. Dengue en Colombia: epidemiología de la reemergencia a la hiperendemia. Primera edición. Bogotá; 2012. p. 18-32.
3. Instituto Nacional de Salud. Boletín de Vigilancia de Dengue en Colombia. Grupo ETV. Boletín 6. Fecha de consulta: 23 de enero de 2012. Disponible en: http://reliefweb.int/sites/reliefweb.int/files/reliefweb_pdf/node-472915.pdf.
4. World Health Organization. Dengue hemorrhagic fever diagnosis treatment and control. Fecha de consulta: 15 de enero de 2012. Disponible en: http://www.who.int/csr/resources/publications/dengue/Denguepublication/en/print. html.
5. Becerra A, Warke RV, de Bosch N, Rothman AL, Bosch I. Elevated levels of soluble ST2 protein in dengue virus infected patients. USA. Cytokine. 2008;41:114-20. http://dx.doi.org/10.1016/j.cyto.2007.11.001.
6. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149-60. http://dx.doi.org/10.1002/path.2287.
7. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11:480-96.
8. Huang Y, Sheikh MS. TRAIL death receptors and cancer therapeutics. Rev Toxicol Appl Pharmacol. 2007;224:284-9. http://dx.doi.org/10.1016/j.taap.2006.12.007.
9. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818-21. http://dx.doi.org/10.1126/science.277.5327.818.
10. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004;95:777-83. http://dx.doi.org/10.1111/j.1349-7006.2004.tb02181.x.
11. Daubener W, Spors B, Hucke C, Adam R, Stins M, Kim KS, et al. Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2, 3-dioxygenase. Infect Immun. 2001;69:6527-31. http://dx.doi.org/10.1128/IAI.69.10.6527-6531.2001.
12. Obojes K, Andres O, Kim KS, Daubener W, Schneider J. Indoleamine 2, 3-dioxygenase mediates cell type-specific anti-measles virus activity of gamma interferon. J Virol. 2005;79:7768-76. http://dx.doi.org/10.1128/JVI.79.12.7768-7776.2005.
13. Oberdörfer C, Adams O, MacKenzie CR, De Groot CJ, Däubener W. Role of IDO activation in anti-microbial defense in human native astrocytes. Rev Med Biol. 2003;527;15-26.
14. King NJ, Thomas SR. Molecules in focus: Indoleamine 2,3-dioxygenase. Biochem Cell Biol. 2007;39:2167-72. http://dx.doi.org/10.1016/j.biocel.2007.01.004.
15. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Rev Biochem Biophys Res Commun. 2001;284:1104-8.http://dx.doi.org/10.1006/bbrc.20015090.
16. Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164:277-81.
17. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy. 2002;32:1520-6.http://dx.doi.org/10.1046/j.1365-2745.2002.01494.x.
18. Long HT, Hibberd ML, Hien TT, Dung NM, van Ngoc T, Farrar J, et al. Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection. J Infect Dis. 2009;199:537-46. http://dx.doi.org/10.1086/596507.
19. King CA, Marshall JS, Alshurafa H, Anderson R. Release of vasoactive cytokines by antibody-enhanced dengue virus infection of a human mast cell/basophil line. J Virol. 2000;74:7146-50.
20. Rothman AL, Green S, Libraty DH, Ennis FA. Dengue: Translating scientific progress into workable solutions. Anti Infect Ther. 2005;3:689-92.
21. Kurane, I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis. 2007;30:329-40.http://dx.doi.org/10.1016/j.cimid. 2007.05.010.
22. Yadav M, Kamath KR, Iyngkaran N, Sinniah M. Dengue hemorrhagic fever and dengue shock syndrome: Are they tumor necrosis factor-mediated disorders. FEMS Microbiol Immunol.1991;4:45-9.http://dx.doi.org/10.1016/0378-1097 (91)90062-F.
23. Warke RV, Martin KJ, Giaya K, Shaw SK, Rothman AL, Bosch I. TRAIL is a novel antiviral protein against dengue virus. J Virol. 2008;82:555-64. http://dx.doi.org/10.1128/JVI.01694-06.
24. Organización Mundial de la Salud. Dengue y dengue hemorrágico. Fecha de consulta: 23 de agosto de 2011. Disponible en: http://www.who.int/mediacentre/factsheets/fs117/es/index.html.
25. TDR/WHO. Dengue guidelines for diagnosis, treatment, prevention and control. Third edition. Geneva: WHO; 2009. p. 2.
26. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg. 1988;38:172-80.
27. Dong T, Moran E, Vinh Chau N, Simmons C, Luhn K, Peng Y, et al. High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PLoS One. 2007;2:e1192. http://dx.doi.org/10.1371/journal. pone.0001192.
28. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003;9:921-7. http://dx.doi. org/10.1038/nm887.
29. Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, Dung NT, et al. Dengue in Vietnamese infants-results of infectionenhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. Infect Dis. 2008;198:516-24. http://dx.doi. org/10.1086/590117.
30. Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, Le BL, et al. Dengue hemorrhagic fever in infants: A study of clinical and cytokine profiles. J Infect Dis. 2004;189:221-32. http://dx.doi.org/10.1086/380762.
31. Becerra A, Warke RV, Martin K, Xhaja K, de Bosch N, Rothman AL, et al. Gene expression profiling of dengue infected human primary cells identifies secreted mediators in vivo. Med Virol. 2009;81:1403-11. http://dx.doi.org/10.1002/jmv.21538.
32. Chen YC, Wang SY. Activation of terminally differentiated human monocytes/macrophages by dengue virus: Productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect oflipopolysaccharide. J Virol. 2002;76:9877-87. http://dx.doi. org/10.1002/jmv.21538.
33. Hober D, Nguyen TL, Shen L, Ha DQ, Huong VT, Benyoucef S, et al. Tumor necrosis factor alpha levels in plasma and whole-blood culture in dengue-infected patients: Relationship between virus detection and pre-existing specific antibodies. J Med Virol. 1998;54:210-8. http://dx.doi. org/10.1002/(SICI)1096-9071(199803)54:3<210::AIDJMV12>3.0.CO;2-L.
34. Houghton TN, Salgado DM, Rodríguez JA. Levels of soluble ST2 in serum associated with severity of dengue due to tumour necrosis factor alpha stimulation. J Gen Virol. 2010;91:697-706. http://dx.doi.org/10.1099/vir.0.012971-0.
35. Ishikawa EM, Nakazawa M, Yoshinari M, Minami M. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice. J Virol. 2005;79:7658-63. http://dx.doi.org/10.1128/JVI.79.12.7658-7663.2005.
36. Sato KT, Nakaoka N, Yamashita H, Yagita H, Kawasaki C, Morimoto M, et al. TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J Immunol. 2005;174:4025-33.
37. Becerra A, Warke RV, Xhaja K, Evans B, Evans J, Martin K, et al. Increased activity of indoleamine 2,3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function. J Gen Virol. 2009;90:810-81. http://dx.doi.org/10.1099/vir.0.004416-0.
38. Kuno G, Bailey RE. Cytokine responses to dengue infection among Puerto Rican patients. Mem Inst Oswaldo Cruz. 1994;89:179-82. http://dx.doi.org/10.1590/S0074-02761994000200010.
39. Vitarana T, de Silva H, Withana N, Gunasekera C. Elevated tumour necrosis factor in dengue fever and dengue hemorrhagic fever. Ceylon Med J. 1991;36:63-5.
40. Clyde K, Kyle JL, Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol. 2006;80:11418-31. http://dx.doi.org/10.1128/JVI.01257-06.